ClinicalTrials.gg
RecruitingNCT05355415Updated May 8, 2026

Adaptive Optics Imaging of Outer Retinal Diseases

An observational study in Retinal Degeneration, Age-Related Macular Degeneration and Retinitis Pigmentosa, sponsored by Food and Drug Administration (FDA). Recruiting at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Food and Drug Administration (FDA) · Observational

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Retinal Degeneration with a site in United States — 11 open to participants now, 29 under way, 3 of them phase 3. Retinal Degeneration · United States.

Planned enrollment
10th of 21
100 · median 83
Started
2021
with 8 others
Observational
22 of 84
6 open now
Primary completion
2028-09
later than 20 of 26 live
Registered
63rd of 84
by date

Among the 84 studies in Retinal Degeneration with a site in United States, this one is the 10th largest by planned enrollment of the 21 observational ones that give a count, is one of 9 that started in 2021, is one of 22 observational ones, reaches primary completion later than 20 of the 26 other live ones, and was the 63rd registered.

Retinal Degeneration

132 studies on the registry are indexed under Retinal Degeneration; 23 are open to participants now.

Browse Retinal Degeneration studies →

Open to participants now

11 of the 84 studies in Retinal Degeneration with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Retinal Degeneration studies recruiting now, 10 (67%) set no upper age limit and 3 (20%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 21 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Retinal Degeneration with a site in United States, or all of them as a file.
02

Study summary

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

Read the detailed description

Objective: The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.

Study Population: Up to fifty (50) healthy volunteers without eye disease (Cohort 1) and up to fifty (50) affected participants with any type of outer retinal disease (Cohort 2) will be enrolled.

Design: This is a longitudinal study protocol where participants will be imaged with investigational multimodal AO (mAO) retinal imaging systems that include optical coherence tomography (OCT) and scanning laser ophthalmoscopy (SLO) channels over three years. High resolution OCT and SLO videos will be collected while the instruments automatically detect and correct for image distortion caused by ocular aberrations. In general, videos of different retinal cellular structures will be acquired from several retinal locations using various imaging modes.

Outcome Measures: The primary outcomes for this protocol are development of new diagnostic methods and disease biomarkers, investigation of cellular morphological and functional changes due to various outer retinal diseases, and development of new AO clinical endpoints for novel therapies.

03

Conditions studied

  • Retinal Degeneration
  • Age-Related Macular Degeneration
  • Retinitis Pigmentosa
  • Hydroxychloroquine Retinopathy
  • Usher Syndromes
  • Late-Onset Retinal Degeneration
  • Cone Dystrophy
  • Cone Rod Dystrophy
  • Rod Cone Dystrophy
  • Rod Dystrophy
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All study participants will be recruited from the NIH patient population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are 21 years of age or older,
  2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),
  3. Have the ability to understand and sign an . (Non-English speaking participants will not be enrolled into the study), and
  4. Have been diagnosed with outer retinal disease or condition (Cohort 2).

Exclusion criteria

Exclusion Criteria:

  1. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),
  2. Have visual correction outside of the range +4 diopters (D) to -8 D,
  3. Have a history of adverse reaction to mydriatic drops,
  4. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or
  5. Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH/NEI AIs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Outer retinal disease

    Subjects with outer retinal disease affecting the photoreceptor-retinal pigment epithelium complex will be classified by clinical exam by an experienced retina specialist. Outer retinal disease subjects will undergo adaptive optics (AO) imaging of several macular locations.

    Device: Adaptive optics imaging

  • Healthy control

    Age-matched healthy control subjects will undergo the same AO imaging procedures as subjects with outer retinal diseases.

    Device: Adaptive optics imaging

Interventions

  • DeviceAdaptive optics imaging

    Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging

06

What researchers measure

Primary outcomes

  1. Photoreceptor (PR) density

    PR density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes or average AOSLO frames.

    Time frame: PR density will be calculated once at the AO imaging session in which PRs are the target.

  2. Retinal pigment epithelial (RPE) cell density

    RPE cell density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes.

    Time frame: RPE cell density will be calculated once at the AO imaging session in which RPE cells are the target.

  3. RPE cell organelle motility

    RPE cell organelle motility will be calculated from the decorrelation time constant for cells segmented from a sequence of AO-OCT volumes.

    Time frame: RPE motility will be calculated once at the AO imaging session in which RPE cells are the target. For the reproducibility portion of the study, RPE organelle motility will be quantified three times separated by 1-2 weeks.

  4. PR cell function

    Photoreceptor cell (cone) function will be measured from phase changes between inner segment - outer segment junction and cone outer segment tip signals in a sequence of AO-OCT volumes collected during visible light stimulation.

    Time frame: PR function will be calculated once at the AO imaging session in which PR cells are stimulated. For the reproducibility portion of the study, PR cell function will be quantified three times separated by 1-2 weeks.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified AO images will be shared with external academic collaborators.

Time frame: For the duration of the study.

Access criteria: Available upon request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Sep 2028, 85 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
May 2, 2022
StartActual
Aug 27, 2021
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05355415
Lead sponsor
Food and Drug Administration (FDA)
Responsible party
Daniel X. Hammer (Deputy Director, Division of Biomedical Physics, Food and Drug Administration (FDA)) — Principal investigator
First posted
May 2, 2022
Start date
Aug 27, 2021
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
May 8, 2026

Study contacts

Daniel X Hammer, Ph.D.
Contact
daniel.hammer@fda.hhs.gov
301-796-9320
Zhuolin Liu, Ph.D.
Contact
zhuolin.liu@fda.hhs.gov
301-796-7914
Daniel X Hammer, Ph.D.
principal investigator · Food and Drug Administration (FDA)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion